Table 2.
Variables associated with presence/absence of liver steatosis in HIV monoinfected patients.
| Characteristics | No steatosis n = 67 | Steatosis n = 31 | PR (95% Cl)a Unadjusted | P univariate | Adjusted PR (95% Cl)a | P multivariate |
| Demographics | ||||||
| Age (years) | 48 ± 12 | 51 ± 10 | 1.02 (0.99–1.04) | 0.146 | ||
| Gender, male (%) | 31 (46.3) | 22 (71.0) | 2.07 (1.07–4.04) | 0.032 | 2.99 (1.15–8.45) | 0.030 |
| BMI (Kg/m2)* | 25.2 (23–27.8) | 26.8 (24.9–29.6) | 1.08 (1.03–1.13) | 0.006 | 1.13 (1.02–1.30) | 0.032 |
| Hypertension (%) | 19 (28.4) | 8 (25.8) | 0.91 (0.47–1.79) | 0.795 | ||
| IFG/Diabetes (%) | 19 (28.4) | 16 (51.6) | 1.92 (1.08–3.40) | 0.025 | 2.21 (0.79–6.24) | 0.130 |
| MS (%) | 17 (25.4) | 14 (45.2) | 1.64 (0.93–2.90) | 0.090 | 1.20 (0.40–3.50) | 0.778 |
| HIV | ||||||
| Time since HIV (years)* | 14 (4–2) | 16 (9–20) | 1.02 (0.98–1.06) | 0.310 | ||
| Time on ART (years)* | 9 (3–17) | 13 (7–16) | 1.03 (0.99–1.07) | 0.128 | ||
| CD4 count (cells/µL)* | 680 (539–864) | 607 (538–828) | 1.00 (1.00–1.01) | 0.484 | ||
Abbreviations: BMI, body mass index; IFG, impaired fasting glucose; MS, metabolic syndrome; ART, antiretroviral therapy; PR, prevalence ration; CI, confidence interval.
Median (IQR)*.
aPrevalence ratio and confidence intervals were estimated using Poisson regression.